13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02977533
(ClinicalTrials.gov)
December 1, 201628/11/2016A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple SclerosisA Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple SclerosisProgressive Multiple SclerosisDrug: GZ402668;Drug: Placebo;Drug: AcyclovirSanofiNULLCompleted18 Years65 YearsAll20Phase 1Germany
2NCT02282826
(ClinicalTrials.gov)
October 201431/10/2014A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple SclerosisA Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple SclerosisProgressive Multiple SclerosisDrug: GZ402668;Drug: placebo;Drug: acyclovirGenzyme, a Sanofi CompanyNULLCompleted18 Years65 YearsBoth48Phase 1Germany